TXMD compared with MREO: revenue, margins and what each company keeps, and the suppliers and customers both name

TXMDTherapeuticsMD, Inc.

Mkt capRevenueRevenue

MREOMereo BioPharma Group plc

Mkt capRevenueRevenue

Compare

TXMDTherapeuticsMD, Inc.

MREOMereo BioPharma Group plc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

TXMDTherapeuticsMD, Inc.

1.80▼−1.15%

Mkt cap$21.2MRevenue$869,000Q2 FY26Revenue$3MFY25

MREOMereo BioPharma Group plc

0.28▼−7.29%

Regular sessionNov 5 '26

Mkt cap$48.4MRevenue$500,000Q2 FY25Revenue—

Compare

Regular sessionNov 5 '26

TXMDTherapeuticsMD, Inc.

MREOMereo BioPharma Group plc

1.80▼−1.15%

Price

0.28▼−7.29%

$21.2M

Mkt cap

$48.4M

Q2 FY26$869,000

Revenue

$500,000Q2 FY25

FY25$3M

Revenue

—

TXMD1.80▼−1.15%vsMREO0.28▼−7.29%Regular sessionNov 5 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

TXMD: latest quarter not drawable. MREO: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only TXMD 0

None

Shared 0

No disclosed counterparties: TXMD.

Only MREO 4

RAREUltragenyx Pharmaceuticalcustomer

AZNAstraZeneca ABsupplier

—Feng Biosciencesunlistedcustomer

—ReproNovounlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

TXMD, solidMREO, dashed